Literature DB >> 7702047

Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment.

J J Rydel1, S M Korbet, R Z Borok, M M Schwartz.   

Abstract

The authors performed a retrospective clinicopathologic study in 81 patients with primary focal segmental glomerular sclerosis (FSGS) to determine whether they could identify clinical or histologic features at presentation that could be predictive of outcome and response to therapy. Males constituted 58% of patients, and 53% were black. At biopsy the patients were 40 +/- 17 years old; 74% were nephrotic, and renal insufficiency was present in 62%. The average time from presentation to biopsy was 16 months, and the average total follow-up was 62 months. Nephrotic patients had a significantly poorer prognosis as compared with nonnephrotic patients (5- and 10-year survivals of 76% and 57% v 92% and 92%; P < 0.05). A multivariate analysis was done on histologic and clinical features at biopsy, assessing for risk factors leading to end-stage renal disease, showing only the serum creatinine and the degree of interstitial fibrosis to have a significant correlation. Thirty nephrotic patients received prednisone, with a treatment time of 5.5 +/- 4 months and a total dose of 5.9 +/- 2.9 g per course of treatment. Fifteen of these patients (50%) achieved a remission by 3.7 +/- 2 months (10 complete remission and 5 partial remissions), with all patients responding within 9 months. Only two patients had spontaneous remissions (both partial). The 5- and 10-year survival for patients in remission were both 100% as compared with 66% and 41% (P < 0.01), respectively, for nephrotic patients not in remission. No clinical feature at presentation of biopsy was predictive of response to therapy when a multivariate analysis was performed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702047     DOI: 10.1016/0272-6386(95)90120-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  57 in total

1.  Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Authors:  Monique E Cho; Mary H Branton; David A Smith; Linda Bartlett; Lilian Howard; James C Reynolds; Donald Rosenstein; Sanjeev Sethi; M Berenice Nava; Laura Barisoni; Fernando C Fervenza; Jeffrey B Kopp
Journal:  Am J Nephrol       Date:  2019-04-09       Impact factor: 3.754

Review 2.  The clinical trial imperative.

Authors:  Debbie Gipson; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

3.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

4.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

Review 5.  Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature.

Authors:  M Colovic; V Jurisic; G Jankovic; D Jovanovic; L J Nikolic; J Dimitrijevic
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 6.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

7.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

8.  Urinary Fibrinogen as a Predictor of Progression of CKD.

Authors:  Hongtian Wang; Chunxia Zheng; Yinghui Lu; Qi Jiang; Ru Yin; Ping Zhu; Minlin Zhou; Zhihong Liu
Journal:  Clin J Am Soc Nephrol       Date:  2017-09-13       Impact factor: 8.237

Review 9.  Treatment of steroid-resistant nephrotic syndrome in the genomic era.

Authors:  Adam R Bensimhon; Anna E Williams; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2018-10-02       Impact factor: 3.714

10.  Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis.

Authors:  Sean J Barbour; Daniel C Cattran; Gabriela Espino-Hernandez; Michelle A Hladunewich; Heather N Reich
Journal:  Kidney Int       Date:  2015-08-19       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.